International cannabis company jumps into the global 57 billion dollar cannabis market. Phoenix Life Sciences International Limited (PLSI) and the international cannabis market set to explode.
With cannabis stocks moving back into the spotlight in the heat of incredible money flows and market action over recent weeks, we have been obsessively looking out for sharp plays that the crowd has missed – stocks that fit a top-tier description, but that haven’t been picked up yet in the markets.
These stocks offer the most potential right now as we see it. And PLSI is the current king of that hill according to our analysis.
Learn More About PLSI at your brokerage today!
The company is one of the very few integrated players, with an end-to-end operational strategy that covers everything – farm to table – from cultivation of cannabis to distribution of refined products that span a fast-tracked pipeline attacking $1.14 trillion in total market footprint.
The company is also already global in its strategy, which may set it apart as well.
Company: Phoenix Life Sciences International Limited
Company Website: https://plsi.co/
- PLSI is possibly the most impressive cannabis play that the crowd hasn’t found yet.
- PLSI is already working with federal governments and national healthcare systems.
- PLSI is starting to see major topline growth, with quarterly y/y revs increasing sharply.
- PLSI is coming off an RSI trough under 51, pointing to a massively oversold stock now heading back the other way.
- PLSI just recorded a MACD Bullish reversal, suggesting a technical change in trend.
- PLSI has developed a deep pipeline of cannabis treatment options addressing some of the biggest healthcare markets.
Phoenix Life Sciences International Limited (OTCMKTS: PLSI) is an adaptive healthcare solutions company. PLSI is in business to advance research and integrate programs and manufacturing of products that target and treat diabetes, pain, cancer, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders.
The company strives to create partnerships and integrate these programs for human health into communities worldwide as part of its Global Health Initiative.
According to company materials, “Phoenix Life Sciences International Limited is headquartered in Denver, Colorado. Over the past four years, many of our partner organizations have worked hard to develop and access a broad range of industry and pharmacology specialists. The partnership includes botanists, biologists, industrial and organic chemists, medical doctors, researchers, packagers and distributors. We are delighted to announce that in September 2018 we merged many of these partnerships and affiliations together under the name Phoenix Life Sciences International Limited. Without the support and collaboration of many individuals, this vision wouldn’t have been realized and we thank them for their global vision.”
As far as recent catalysts, the company just announced its common stock is now publicly traded in the United States, trading under the symbol OTC: PLSI and released some initial statements on its global production strategy for cannabinoid-based healthcare solutions.
According to the release, Phoenix Life, which is a consolidation of multiple domestic and international businesses including Stem BioScience, Inc., Blue Dragon Ventures, along with the MediJane brand, aims to be the premier global healthcare company that changes the way that many diseases and conditions are treated around the world.
“We are confident that we will be able to impact the health and wellbeing of millions of people around the world with our highly-sophisticated cannabis derived formulations and our unique production and distribution models,” said Martin Tindall, incoming Chief Executive Officer of Phoenix Life Sciences International. “I am excited to help guide the company to success and remain committed to the vision of life-enhancement through better healthcare.”
Following that announcement, the company also hit the wires to provide an update on the completion of merger documents with the Secretary of State in Nevada, as well as appointed a new renowned audit firm and retired a substantial amount of convertible debt.
As a part of the final steps of its merger that created Phoenix Life Sciences International Limited, documents were processed through the Secretary of State for Nevada. The documents, including form and certificate of merger, were received back by the company, leaving only this week’s boards of directors’ appointments in the finalization of the company merger.
In other words, it’s all systems go for PLSI at this point.
Which brings us to this very interesting chart. Shares of the stock have started to move with some bullish potential under the surface of the tape.
The stock recently broke out above its 200-day simple moving average on increasing volume. As noted above, the stock has one of the smallest trading floats we have ever come across (under 525k shares). That means any influx of buying interest will send this to the moon.
You can see a good example of this back in January of this year, when PLSI went from $2.50/share to $90/share in 6 days. That’s no joke. And it could happen from here given this tiny float and the increasing attention being paid to the cannabis space.
Remember, this is one of the only true global integrated cannabis players out there.
Latest News On PLSI
DENVER, CO, March 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”, the “Company”), an international adaptive healthcare solutions company, today announced that it has filed its Form 10-K Annual Reports, including audited financial reports, with the Securities and Exchange Commission (“SEC”) for the 2015 and 2016 fiscal years as part of the merger and consolidation completed at the end of 2018. Phoenix Life was created through a consolidation of multiple domestic and international businesses. As final audits are being completed for the 2017 and 2018 fiscal years, corresponding 10-K Annual Reports will likewise be filed, providing prospective and current shareholders with current reporting.
DENVER, CO, March 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”, ”the Company”), an international adaptive healthcare solutions company, today announced that it has broken ground on its first Community Clinic and Dispensing Pharmacy for the treatment of diabetes in the Republic of Vanuatu. The Company held a groundbreaking event at 11:00 a.m. on March 5th in Erakor Village, Vanuatu where the Paramount Chief welcomed Phoenix Life officials, such as Global Head of Security and Transport, Former Police Commissioner John Taleo, Head of National Healthcare, Former Director of Port Vila Central Hospital, the Department of Curative & Hospital Services and Vanuatu’s Ministry of Health, Dr. Santus Wari, and Martin Tindall, Phoenix Life CEO and Founder.
DENVER, CO, Feb. 27, 2019 -- via NEWMEDIAWIRE -- Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”), an international adaptive healthcare solutions.
DENVER, CO, Feb. 01, 2019 -- via NEWMEDIAWIRE -- Phoenix Life Sciences International Limited (OTC: PLSI) (“Phoenix Life”), an international adaptive healthcare solutions.
ATLANTA, GA / ACCESSWIRE / January 16, 2019 / CannaInvestor Magazine announced today Phoenix Life Sciences International Limited (OTC PINK: PLSI) (''Phoenix Life''), an international adaptive healthcare ...
DENVER, CO, Jan. 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”, or the “Company”), an international adaptive healthcare solutions company, today announced its 2019 strategy for continued international expansion to its shareholders. Today, I am happy to share with you the Phoenix Life strategy for expansion in 2019. The first step the company is making to further its mission is the establishment of offices and infrastructure in the Oceania region including Australia and the Republic of Vanuatu. Further, this will include the recruitment of an expanded team of medical, clinical trial, agricultural and pharmaceutical personnel.
DENVER, CO, Dec. 19, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that Mohyuddin Mirza has joined the company as the Botany Specialist. Dr. Mohyuddin Mirza has over three decades of experience in the management of greenhouse crops from farm to consumers including Echinacea, Rhodeola, and Cannabis and has made a significant economical impact on the botanical products industries in Alberta, Canada. “As Phoenix Life Sciences International moves forward with company expansion in the new year, we are proud to recruit the most well-respected specialists in the growing industry, like Mohyuddin Mirza,” said Phoenix Life Sciences International CEO Martin Tindall.
Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that it is now accepting bids from U.S. licensed producers of industrial hemp to supply various products to be used in the formulation of its botanical pharmaceuticals. “As we move forward with our mission of transforming the future of global healthcare, our next step is partnering with a GMP licensed hemp producers in the U.S. that shares our values and mission to push botanical pharmaceuticals forward throughout the world,” said Phoenix Life CEO Martin Tindall. Phoenix Life is seeking a Good Manufacturing Practice (GMP) licensed industrial hemp partner for both U.S. and foreign markets to commence in January 2019.
Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that Angus Stewart has joined the company as the Agriculture and Horticulture Senior Advisor. Angus Stewart has over two decades of experience specializing in horticulture and is currently an Agricultural and Horticultural Scientist and Consultant Plant Breeder of approximately 100 commercially released plant cultivars. Additionally, Stewart has extensive experience with plant breeding techniques of all levels and is well versed in the best practices for the production and extraction of botanical active ingredients like cannabinoids.
Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced that it has received an import certificate from the Republic of Vanuatu’s Minister of Health to bring its cannabis diabetes drug Phoenix Metabolic into the country for clinical trials. “With this certificate, we look forward to playing a pivotal role in decreasing the size of the global diabetes epidemic,” said Phoenix Life Sciences International CEO Martin Tindall. Phoenix Life can now import its cannabis-based diabetes drug into Vanuatu and the company hopes to soon announce the launch of clinical trials for its first 1,000 patients.
Phoenix Life Sciences International Limited (“Phoenix Life”) (PLSI), an international adaptive healthcare solutions company, today announced that it has retired additional convertible debt, positioning the company with no more outstanding preferred shares or debt that is subject to conversion. As a part of the implementation of its fiscal policy aimed at bringing shareholders value and forwarding the company's mission of creating a global platform for plant-based pharmaceuticals, including bringing medical cannabis products into the mainstream of healthcare, the company has retired its outstanding Series C debt and canceled its Series A and B. “To operate under the umbrella company Phoenix Life Sciences International, we executed the consolidation of various entities and focused on eliminating as much expensive debt as possible,” said Martin Tindall, Chief Executive Officer of Phoenix Life Sciences International.
Phoenix Life Sciences International Limited (PLSI) (“Phoenix Life”), an international adaptive healthcare solutions company, today announced it has completed the last stages the consolidation of businesses and received approval from the Financial Industry Regulatory Authority (“FINRA”) of the corporate action completing its name change and change of stock symbol. “After five years of planning and hard work, we could not be more excited to have completed this consolidation to build a world changing organization,” said Martin Tindall, CEO of Phoenix Life Sciences International. “This marks the end of what has been a long transitional period for our company and the beginning of a new chapter of opportunity for Phoenix Life.
Phoenix Life Sciences International Limited (OTC:PLSI) is creating a global platform for the re-introduction of organic, plant based pharmaceuticals and programs for creating healthcare solutions and reducing total cost of national healthcare programs
“Our business is to advance research and integrate programs and manufacturing of products that target and treat; diabetes, pain, cancers, and address psychological, gastrointestinal, autoimmune, neurological and sleep disorders.
Creating partnerships for integrating these programs for human health into communities worldwide as part of our Global Health Initiative. Working with developing nations on programs to improve affordable healthcare and creating industry.
Phoenix Life Sciences uses organically produced plants, including cannabis, extracts the purist of active ingredients and encapsulates them for maximum bio availability and efficacy. Providing a patient-centric alternative to the low efficacy and the high side effects of conventional pharmaceuticals. Giving doctors and their patients an easy to take, easy to manage, accurately dosed natural healthcare solution.
Phoenix Life Sciences International is targeting to build production to service over 2.5 million patients over the next 5 years.”
Key Team Members:
Martin Tindall, CEO and Founder
Tindall has an extensive career in large scale organizational change. His career focus has been in the integration of technology with international trade and finance. Initially trained in accounting and commercial and company law, he has held various roles including Chief Information Officer at Bartercard, Executive Director of Kronos International Investments and particularly enjoyed environmental projects that deliver sustainability.
Starting Phoenix in 2013, after the death of his father from chemotherapy treating his pancreatic cancer, Tindall is devoted to providing advancement in the treatment of cancer, diabetes and other diseases using safe, non-toxic, plant based pharmaceutical solutions.
Janelle Marsden, Managing Director
Marsden has held senior roles across many industry sectors. Trained at a master’s level in construction, architecture and finance, she has been awarded senior roles over the past 20 years in both the public and private sector. Having lived in Australia, U.S. and Italy, Marsden has worked on large scale implementation projects and managed large agriculture developments. Marsden’s skills include agricultural grow, product implementation, organization and marketing. She has been the chair and board member of tourism, economic development and food and wine entities and has demonstrated her ability to drive and grow industries from the ground up. Marsden will also directly over see the infrastructure developments and ensure that Phoenix continues to meet its environmental, financial, timely and quality outcome.
Learn More About PLSI at your brokerage today!
Legal Notice: This work is based on what we’ve learned as financial journalists. It may contain errors and you should not base investment decisions solely on what you read here. It’s your money and your responsibility. Nothing herein should be considered personalized investment advice. Although our employees may answer general customer service questions, they are not licensed to address your particular investment situation. Our track record is based on hypothetical results and may not reflect the same results as actual trades. Likewise, past performance is no guarantee of future returns. Don’t trade in these markets with money you can’t afford to lose. Investing in stock markets involves the risk of loss. Before investing you should consider carefully the risks involved, if you have any doubt as to suitability or the taxation implications, seek independent financial advice. StocksnTrade expressly forbids its writers from having a financial interest in their own securities or commodities recommendations to readers. Such recommendations may be traded, however, by other editors, StocksnTrade, its affiliated entities, employees, and agents, but only after waiting 24 hours after an internet broadcast.
(c) 2018 StocksnTrade. All Rights Reserved. Protected by copyright laws of the United States and treaties. This Newsletter may only be used pursuant to the subscription agreement. Any reproduction, copying, or redistribution, (electronic or otherwise) in whole or in part, is strictly prohibited without the express written permission of StocksnTrade. See site disclaimer for compensation.